Your search matched 256 results
We’ve recapped Scott Gottlieb’s eventful penultimate week at the FDA in this week’s edition of The Week That Was.
This week's edition of The Week That Was details how health and medical groups are taking action to address the “greatest public health challenge of the 21st century” and what you need to know from a busy week in healthcare policy.
This week’s edition of The Week That Was looks at how not to spin a poor earnings report.
In this week’s edition of The Week That Was, we analyze recent public apologies.
In this week’s edition of The Week That Was, we dig into the Administration’s plan, the debate over the policy and what’s next.
We’ve analyzed their progress in this week’s issue of The Week That Was.
In this week’s edition of The Week That Was, we explain one way they can communicate value.
Check out the Week That Was for the answer.
We’re talking CBD in this week’s edition of The Week That Was.
A busy week in Washington | Blog
So, a lot happened in Washington this week… which we won’t be commenting on!
The Week That Was: I do, Ms. | Blog
In this week’s edition of The Week That Was, we discuss the rule, the reactions and what it means for patients, providers and pharma.
Read this and more in this week's TWTW!
This week’s edition of The Week That Was takes a look and provides insights from a new ICER report.
Take a look at the latest insights in this week’s issue of The Week That Was.
We’ve got a recap for you in this week’s edition of The Week That Was.
No matter whether you were the lone staffer in your office or relaxing on a beach somewhere this past week, we’ve got the run down on the latest healthcare headlines—the good, the bad and the ugly—to help you get you back up to speed.
In this week’s edition of The Week That Was, the team digs into the bill and its implications.
The Week That Was: ... | Blog
It’s all in the latest edition of The Week that Was.
It was another intense week in healthcare headlines.
House of Representatives for a vote in just a few weeks.
The anti-vaccination movement is causing challenges not just in healthcare, but now in tech.
Employers wield enormous influence in deciding the care their employees receive – yet they aren’t always considered a core “stakeholder” in the healthcare debate.
As the industry awaits a potential executive order on transparency around healthcare costs, we took a look at some transparency tools, and where they’re falling short.
You may have seen a lot of recent reporting on “loss of coverage” for Americans.
AI is to 2019 what blockchain was to 2018.
Prescription delivery services – like Hims, Roman and Kick – are popping up all over the place, prompting concerns about regulation.
Everyone seems to be talking about digital health, but what does that really look like in action?
Climate change is named a top 10 health threat and we’ve broken down the conundrum for pharma companies regarding activating on the issue.
In case you haven’t heard, it’s the New Year.
Drug makers aren’t the only ones under pressure for high costs.